• 1606 Citations

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

We're devoted to understanding the cellular events that influence the aggressiveness of breast tumors, and are currently focused on the following areas: (1) Mechanisms of tumor maintenance and progression medicated by proto-oncogenes (i.e., MYC transcription factor, PIM family of serine/threonine kinases, etc), their activators and effectors, and tumor microenvironment. (2) Biology and therapeutic targetability of novel molecular factors that determine patient clinical outcome.

Training Experience

2014Postdoctoral Fellowship, University of California, San Francisco

Education/Academic qualification

PhD, Indiana University Bloomington

… → 2007

Research interests

  • Bioinformatics
  • Breast Cancer
  • Cancer Biology
  • Cancer Genetics
  • Drug Discovery
  • Immune Regulation
  • Oncology
  • Translational Research

Fingerprint Dive into the research topics where Dai Horiuchi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


  • Research Output

    • 1606 Citations
    • 14 Article
    • 1 Chapter

    Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer

    Brisard, D., Eckerdt, F., Marsh, L. A., Blyth, G. T., Jain, S., Cristofanilli, M., Horiuchi, D. & Platanias, L. C., Dec 1 2018, In : Oncotarget. 9, 99, p. 37305-37318 14 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity

    Kang, H. J., Song, H. Y., Ahmed, M. A., Guo, Y., Zhang, M., Chen, C., Cristofanilli, M., Horiuchi, D. & Vassilopoulos, A., Oct 2018, In : Free Radical Biology and Medicine. 126, p. 358-371 14 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression

    Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., Marsh, L. A., Anderton, B. N., Rohrberg, J., Kunder, R., Bazarov, A. V., Yaswen, P., McManus, M. T., Rugo, H. S., Werb, Z. & Goga, A., Nov 1 2016, In : Nature Medicine. 22, 11, p. 1321-1329 9 p.

    Research output: Contribution to journalArticle

  • 68 Scopus citations

    Linking tumor mutations to drug responses via a quantitative chemical–genetic interaction map

    Martins, M. M., Zhou, A. Y., Corella, A., Horiuchi, D., Yau, C., Rakshandehroo, T., Gordan, J. D., Levin, R. S., Johnson, J., Jascur, J., Shales, M., Sorrentino, A., Cheah, J., Clemons, P. A., Shamji, A. F., Schreiber, S. L., Krogan, N. J., Shokat, K. M., McCormick, F., Goga, A. & 1 others, Bandyopadhyay, S., Jan 1 2015, In : Cancer discovery. 5, 2, p. 154-167 14 p.

    Research output: Contribution to journalArticle

  • 31 Scopus citations

    Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

    Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., Kurupi, R., Moore, P. D., Pinto, J. A., Doimi, F. D., Gómez, H., Horiuchi, D., Goga, A., Lehmann, B. D., Bauer, J. A., Pietenpol, J. A. & 7 others, Ross, J. S., Palmer, G. A., Yelensky, R., Cronin, M., Miller, V. A., Stephens, P. J. & Arteaga, C. L., Feb 1 2014, In : Cancer discovery. 4, 2, p. 232-245 14 p.

    Research output: Contribution to journalArticle

  • 220 Scopus citations